Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

h being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(R); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Contact:
    Michael W. Rogers                    Robin L. DeCarlo
    EVP and Chief Financial Officer      Director, Corporate Communications
    (781) 861-8444                       (781) 402-3405



                        INDEVUS PHARMACEUTICALS, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
             For the three and twelve months ended September 30,
                                2008 and 2007
                 (Amounts in thousands except per share data)

                                         For the three       For the twelve
                                          months ended        months ended
                  
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... 26, 2015  SeraCare Life Sciences, a leading ... announced that it has signed a Cooperative Research ... Institute (NCI), part of the National Institutes of ... for cancer assays.  The CRADA will investigate the ... control DNA biosynthetics spiked into a genomic DNA ...
(Date:6/26/2015)... ... June 26, 2015 , ... ... Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a five year ... in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative ...
(Date:6/26/2015)... (PRWEB) , ... June 26, 2015 , ... ... today announced that its SimplePrep™ technologies have been integrated into a sample prep ... Space Station (ISS) as a part of the NASA’s WetLab-2 Project. , On ...
(Date:6/26/2015)... DALLAS , June 26, 2015 ... Animal Fat), Application (Hydraulic Fluids, Metalworking fluids, Chainsaw oils, ... Automobile) & by Region - Global trends and Forecasts ... expected to reach $2,972.13 Million by 2020 at a ... Browse 160 market data Tables and   66 ...
Breaking Biology Technology:SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3
... TNGN ), a leader in regenerative medicine, today ... on Wednesday, October 27, 2010 in New York, New York. ... product development portfolio and upcoming corporate milestones, and will expand ... The live webcast of the event will be available ...
... Calif., Oct. 12 With more than 200 ... Workshop, Microsoft Research showcases two technologies that facilitate ... a MODISAzure-based environmental service. (Logo: ... Programmers and developers in bioscience now ...
... The Ontario Institute for Cancer Research (OICR) today announced ... Inc., an Ontario company that is developing a software ... detailed disease and treatment data without compromising individual privacy. ... Assessment Tool (PARAT), is currently being used by hospitals ...
Cached Biology Technology:Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 3Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 4OICR Makes Equity Investment in Medical Information Company 2
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... , SANTA ANA, Calif. and ... Microsystems, Inc., d.b.a. Identive Group (Nasdaq: INVE ; Frankfurt ... for the security, identification and RFID industries, today announced that ... three new executives in line with the announced reorganization of ...
... 2010 The Translational Genomics Research Institute (TGen) today ... agreement with the Van Andel Research Institute (VARI) that ... TGen expects the agreement to create a ... and treatments for patient benefit. ...
... Medicine believe they may have discovered how the hormone ... findings will be presented at the Annual Scientific Meeting ... by Errol Norwitz, M.D., professor in the Department of ... Preterm birthdelivery prior to 37 weeks gestationhas become increasingly ...
Cached Biology News:Identive Group Expands Executive Management Team 2Identive Group Expands Executive Management Team 3TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3
... PTOs are internucleotide modifications, where one ... replaced by a sulphur atom. This modification ... are available as Full-PTOs ... with thio-caps Several internucleotide ...
... The VARIOKLAV 75 S and 135 S steam ... double bottoms combine the advantages of a double-walled ... use, effective deaeration and drying by built-in jacket ... - fast cooling. The chamber is free of ...
Request Info...
... catalyzes the transfer of the gamma-phosphate ... single- and double-stranded DNA, RNA, and ... the 3'-phosphate from 3'-phosphoryl polynucleotides, deoxyribonucleoside ... form a 3'-hydroxyl group. Storage Buffer: ...
Biology Products: